Curate Biosciences

3:30 PM - 3:45 PM (PDT), Wednesday, June 15, 2022
Curate Biosciences - Transformative Cell Processing for Next-Generation Therapies

At Curate Biosciences we see a future where patients, clinicians, innovators, and payors routinely embrace cell and gene therapies against intractable disease.

To help make this future a reality, we focus on advancing our platform technology, Deterministic Cell Separation™, to deliver greater quantities of the highest quality cellular starting materials, faster and less costly, to the innovators, developers, and clinicians pushing the boundaries of the possible.

The Curate® Cell Processing System gently isolates leukocytes using Deterministic Cell Separation™ (DCS), an advanced, highspeed microfluidic technology that gently separates cells based on size. Optimized for processing apheresis and cell culture samples, the Curate obtains uniquely larger quantities of healthier leukocytes compared to other separation technologies.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2002
Main Therapeutic Focus:
Lead Product in Development:
Curate
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
chief business officer
gpb scientific